Close Menu

You may find more results for this query on our sister sites: GenomeWeb and 360Dx.

Home › Diagnostics › Drug Discovery & Development › CytoDyn Sees Promising Early Responses in Two Breast Cancer Patients to Leronlimab

CytoDyn Sees Promising Early Responses in Two Breast Cancer Patients to Leronlimab

Dec 24, 2019
|
staff reporter

NEW YORK – Late-stage biotech company CytoDyn announced on Monday that an early trial of its new drug candidate leronlimab (PRO 140) produced a positive clinical response in two patients with metastatic breast cancer. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

May
26
Featured Webinar

CaTCH it if you can! CRISPRa-based Exploration of Therapy Resistant Cell Clones

Sponsored by
Lexogen

The emergence of cell clones that are resistant to targeted therapies poses a significant issue in the treatment of metastatic melanoma.

Jun
16
Featured Webinar

Precision Oncology in Melanoma Patients Treated with Immunotherapy: Clinical and Technological Perspective

Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.

Jun
18
Featured Webinar

Disparities in Precision Oncology: Identifying Barriers and Moving Toward Solutions

Sponsored by
Canexia Health

Last year, by Precision Oncology News' count, the FDA approved 27 precision oncology drugs, a 35 percent increase in the number of approvals from 2019. 

What's Popular?

In Drug Discovery & Development

  1. AACR Study of Eli Lilly's Retevmo Shows Anti-Tumor Activity Across Cancers

  2. Carisma Therapeutics Taps Into Innate Immune System to Extend CAR Therapy to Solid Tumors

    Premium

  3. Immunocore's Tebentafusp Prolongs Survival in Uveal Melanoma Patients, AACR Study Shows

    Premium

  4. Verastem Oncology's Combination Therapy Advances in KRAS-Mutated Lung Cancer

    Premium

  5. Ideaya Biosciences Begins Phase I Trial of MAT2A Inhibitor in Tumors With MTAP Deletion

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.